Bulls REASONS TO BUY
Bears REASONS TO SELL
June 17, 2013
(Stock Blog Hub, 2/11/13)
On Feb 1, we downgraded Quest Diagnostics (DGX), a leading player in the diagnostic testing market, to Underperform based on the company’s dismal fourth-quarter 2012 results...(read more)
(Stock Blog Hub, 12/4/12)
We recently reiterated our Neutral recommendation on Quest Diagnostics (DGX), the leading providers of commercial laboratory services in North America, with a target price of...(read more)
(Wall Street Sector Selector, 5/16/11)
This week we bring reviews of “value stocks” for long-term investors by 24/7 Wall St. Monday’s focus is mostly on large-cap stocks that are easily recognized and which have large positions in their markets. Generally speaking, ...
Quest Diagnostics (DGX) Company Overview
Quest Diagnostics (DGX) is the largest independent research and testing laboratory in the world, holding approximately 14% of the $40 billion laboratory services market. The company provides diagnostic testing, information, and services, for the health care industry, primarily in the United States. Despite having a large domestic presence, Quest also operates in Central and South America and Europe. The company offers routine tests, including blood cholesterol level, blood chemistries, and Pap tests, and esoteric testing services, which includes genetic and immunologic testing, among others. It also provides testing services for clinical trials and risk assessment services for the life insurance industry.
In addition to offering testing services, Quest also manufactures and markets diagnostic and testing equipment for sale to hospitals, other laboratories, physicians, and health insurance companies, to name a few. Quest operates a network of approximately 2,000 patient service centers and principal laboratories, as well as approximately 150 smaller laboratories.(Read more at Wikinvest )
What's in this DGX analysis on Wikinvest...